Key facts
- Tahoe’s last known valuation is $131.0M (Aug 2025).
- It has raised $50.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($35.0M) in Aug 2025.
- Notable investors include General Catalyst, Mubadala Investment Company, AWS Startups, Wing Venture Capital, Amplify Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Tahoe
Funding rounds
1 roundsAbout Tahoe
Operator of a biotech company intended to combine data to find better targets and drugs that can treat patients. The company's platform engages in generating scalable, single-cell precision to capture the context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays, enabling doctors to improve the failure rate of drugs in clinical trials.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 25
- Website
- tahoebio.ai/
- Ownership
- Privately Held (backing)
Tahoe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tahoe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tahoe in its N-PORT filings yet. We sweep new filings monthly.